NYSE:PFE - Pfizer Stock Price, Price Target & More

Pfizer trades on the New York Stock Exchange (NYSE) under the ticker symbol "PFE."

Pfizer declared a quarterly dividend on Thursday, April 26th. Investors of record on Friday, May 11th will be paid a dividend of $0.34 per share on Friday, June 1st. This represents a $1.36 dividend on an annualized basis and a yield of 3.76%. The ex-dividend date is Thursday, May 10th. View Pfizer's Dividend History.

Pfizer announced that its board has approved a stock buyback program on Tuesday, December 19th 2017, which allows the company to repurchase $10,000,000,000.00 in shares, according to EventVestor. This repurchase authorization allows the company to buy shares of its stock through open market purchases. Shares repurchase programs are generally a sign that the company's management believes its stock is undervalued.

Pfizer Inc. (NYSE:PFE) released its earnings results on Tuesday, May, 1st. The biopharmaceutical company reported $0.77 earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of $0.74 by $0.03. The biopharmaceutical company had revenue of $12.91 billion for the quarter, compared to the consensus estimate of $13.14 billion. Pfizer had a return on equity of 25.29% and a net margin of 41.29%. The company's quarterly revenue was up 1.0% on a year-over-year basis. During the same period last year, the firm posted $0.69 earnings per share. View Pfizer's Earnings History.

Pfizer is scheduled to release their next quarterly earnings announcement on Tuesday, August, 7th 2018. View Earnings Estimates for Pfizer.

Pfizer issued an update on its FY18 earnings guidance on Tuesday, May, 1st. The company provided earnings per share (EPS) guidance of $2.90-3.00 for the period, compared to the Thomson Reuters consensus EPS estimate of $2.95. The company issued revenue guidance of $53.5-55.5 billion, compared to the consensus revenue estimate of $54.45 billion.

21 analysts have issued 12 month target prices for Pfizer's stock. Their predictions range from $36.00 to $45.00. On average, they anticipate Pfizer's stock price to reach $40.4167 in the next year. View Analyst Ratings for Pfizer.

Pfizer saw a increase in short interest in May. As of May 31st, there was short interest totalling 61,705,171 shares, an increase of 3.1% from the May 15th total of 63,688,761 shares. Based on an average daily trading volume, of 19,319,820 shares, the days-to-cover ratio is presently 3.2 days. Currently, 1.1% of the shares of the company are sold short.

Some companies that are related to Pfizer include Johnson & Johnson (JNJ), Novartis (NVS), Merck & Co., Inc. (MRK), AbbVie (ABBV), Abbott Laboratories (ABT), Novo Nordisk A/S (NVO), Bayer (BAYRY), GlaxoSmithKline (GSK), Sanofi (SNY), Eli Lilly And Co (LLY), AstraZeneca (AZN), Bristol-Myers Squibb (BMY), Allergan (AGN), Celgene (CELG) and Shire (SHPG).

News articles about PFE stock have trended somewhat positive on Tuesday, Accern Sentiment reports. The research firm identifies negative and positive press coverage by analyzing more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Pfizer earned a news sentiment score of 0.09 on Accern's scale. They also gave media stories about the biopharmaceutical company an impact score of 46.07 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company's share price in the next few days.

Pfizer's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (7.72%), Northern Trust Corp (1.31%), Massachusetts Financial Services Co. MA (1.04%), Dimensional Fund Advisors LP (0.79%), Franklin Resources Inc. (0.75%) and Barrow Hanley Mewhinney & Strauss LLC (0.69%). Company insiders that own Pfizer stock include Albert Bourla, Alexander R Mackenzie, Anthony J Maddaluna, Charles H Hill, Douglas M Lankler, Frank A Damelio, Ian C Read, Kirsten Lund-Jurgensen, Laurie J Olson, Mikael Dolsten, Rady A Johnson, Sally Susman and W Don Cornwell. View Institutional Ownership Trends for Pfizer.

PFE stock was sold by a variety of institutional investors in the last quarter, including Amundi Pioneer Asset Management Inc., Natixis, Swiss National Bank, FIL Ltd, Caisse DE Depot ET Placement DU Quebec, Levin Capital Strategies L.P., MUFG Securities EMEA plc and Legal & General Group Plc. Company insiders that have sold Pfizer company stock in the last year include Alexander R Mackenzie, Charles H Hill, Douglas M Lankler, Frank A Damelio, Ian C Read, Kirsten Lund-Jurgensen, Laurie J Olson, Mikael Dolsten, Rady A Johnson, Sally Susman and W Don Cornwell. View Insider Buying and Selling for Pfizer.

PFE stock was acquired by a variety of institutional investors in the last quarter, including BlackRock Inc., Dimensional Fund Advisors LP, Robeco Institutional Asset Management B.V., Neuberger Berman Group LLC, Mackay Shields LLC, Teacher Retirement System of Texas, LSV Asset Management and Summit Trail Advisors LLC. View Insider Buying and Selling for Pfizer.

Shares of PFE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of PFE stock can currently be purchased for approximately $36.19.

Pfizer has a market capitalization of $216.45 billion and generates $52.55 billion in revenue each year. The biopharmaceutical company earns $21.31 billion in net income (profit) each year or $2.65 on an earnings per share basis. Pfizer employs 90,200 workers across the globe.

Pfizer's mailing address is 235 EAST 42ND STREET, NEW YORK NY, 10017. The biopharmaceutical company can be reached via phone at 212-733-2323.